A score for predicting response to pharmacotherapy in obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 315-322

  Denys, Damiaan ^a,b   Burger, Huibert ^b   Van Megen, Harold ^a   De Geus, Femke ^a   Westenberg, Herman ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antidepressants; Obsessive compulsive disorder; Pharmcotherapy; Prediction

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL SIGNIFICANCE;

ADOLESCENT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0842309252     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200311000-00002     Document Type: Article

References (51)

1. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ (1994). Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 14:247-254.
2. Ackerman DL, Greenland S, Bystritsky A (1996). Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol Bull 32:157-165.
3. Ackerman DL, Greenland S, Bystritsky A (1998). Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 18:185-192.
4. Ackerman DL, Greenland S, Bystritsky A (1999). Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 19:459-465.
5. Alarcon RD, Libb JW, Spitler D (1993). A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol 13:210-213.
6. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J (2001). Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 62:535-540.
7. Arntz A, van Beijsterveldt B, Hoekstra R, Hofman A, Eussen M, Sallaerts S (1992). The interrater reliability of a Dutch version of the Structured Clinical Interview for DSM-III-R Personality Disorders. Acta Psychiatr Scand 85: 394-400.
8. Baer L, Jenike MA (1992). Personality disorders in obsessive compulsive disorder. Psychiatr Clin North Am 15:803-812.
9. Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J (1992). Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry 49:862-866.
10. Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P (1998). Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 59:420-425.
11. Capstick N, Seldrup J (1973). Phenomenological aspects of obsessional patients treated with clomipramine. Br J Psychiatry 122:719-720.
12. Carrasco JL, Hollander E, Schneier FR, Liebowitz MR (1992). Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psychiatry 53:387-391.
13. Cavedini P, Erzegovesi S, Ronchi P, Bellodi L (1997). Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol 7:45-49.
14. Dales LG, Ury HK (1978). An improper use of statistical significance testing in studying covariables. Int J Epidemiol 7:373-375.
15. De Haan E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, van Dyck R (1997). Prediction of outcome and early versus late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 96:354-361.
16. Denys D, van der Wee N, van Megen HJ, Westenberg HG (2002). Double blind comparison of paroxetine and venlafaxine in obsessive-compulsive disorder. Int J Neuropsychopharmacol 5(suppl 1):131-132.
17. DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S (1990). Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 26:54-59.
18. Drummond LM (1993). The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments. Br J Psychiatry 163:223-229.
19. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L (2001). Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21:488-492.
20. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M (1985). Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42:977-983.
21. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
22. Goodman WK, McDougle CJ, Price LH (1992). Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 53 (suppl):29-37.
23. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH (1993). Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54 (suppl):16-26.
24. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11:21-29.
25. Hamilton M (1959). The assesment of anxiety states by rating. Br J Med Psychol 32:50-55.
26. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
27. Hanley JA, McNeil BJ (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36.
28. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. (2002). Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 63 (suppl 6):20-29.
29. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M (1983). Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40:605-612.
30. Jenike MA, Baer L, Minichiello WE, Schwartz CE, Carey RJ Jr (1986). Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 143:530-532.
31. Leonard HL, Swedo SE, Lenane MC, Rettew DC, Hamburger SD, et al. (1993). A 2-to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50:429-439.
32. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980). Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 136: 1-25.
33. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L (1999). Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 156:1409-1416.
34. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH (1993). The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13: 354-358.
35. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
36. Mundo E, Erzegovesi S, Bellodi L (1995). Follow-up of obsessive-compulsive patients treated with proserotonergic agents [letter]. J Clin Psychopharmacol 15:288-289.
37. Mundo E, Bareggi SR, Pirola R, Bellodi L (1999). Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry 45:290-294.
38. Orloff LM, Battle MA, Baer L, Ivanjack L, Pettit AR, Buttolph ML, Jenike MA (1994). Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 151:441-442.
39. Post RM, Weiss SR (1998). Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression. Biol Psychiatry 44:193-206.
40. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995). Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 56:368-373.
41. Roseboom PH, Kalin NH (2000). Neuropharmacology of venlafaxine. Depress Anxiety 12 (suppl 1):20-29.
42. Sanavio E (1988). Obsessions and compulsions: the Padua Inventory. Behav Res Ther 26:169-177.
43. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (suppl 20):22-33.
44. Stein DJ, Montgomery SA, Kasper S, Tanghoj P (2001). Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:357-361.
45. Steiner M, Gergel IP, Wheadon DE (1996). Predictors of Response to Paroxetine Therapy in OCD. Presented at the Annual Meeting of the American Psychiatric Association, New York.
46. Steketee G (1997). Disability and family burden in obsessive-compulsive disorder. Can J Psychiatry 42:919-928.
47. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S (1999). Predictors of course in obsessive-compulsive disorder. Psychiatry Res 89:229-238.
48. Steyerberg EW, Eijkemans MJ, Habbema JD (1999). Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935-942.
49. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L (1980). Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 37:1281-1285.
50. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, et al. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder [published erratum appears in Arch Gen Psychiatry 1994; 51:864]. Arch Gen Psychiatry 51:559-567.
51. Weinstein MC, Fineberg HV (1980.) Clinical Decision Analysis. Philadelphia: WB Saunders.